• Citer

HER2 staining intensity in HER2-positive disease: Relationship with FISH amplification and clinical outcome in the HERA trial of adjuvant trastuzumab

par Zabaglo, Lila;Salter, Janine;Dowsett, Mitch;Stoss, Oliver;Rüschoff, Josef;Zielinski, Dirk;Arfi, Mounir;Bradbury, Ian;Procter, Marion;Dafni, Urania;Piccart-Gebhart, Martine
Référence Annals of oncology, 24, 11, page (2761-2766), mdt275
Publication Publié, 2013-11

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	HER2 staining intensity in HER2-positive disease: Relationship with FISH amplification and clinical outcome in the HERA trial of adjuvant trastuzumab
Auteur:	Zabaglo, Lila; Salter, Janine; Dowsett, Mitch; Stoss, Oliver; Rüschoff, Josef; Zielinski, Dirk; Arfi, Mounir; Bradbury, Ian; Procter, Marion; Dafni, Urania; Piccart-Gebhart, Martine
Informations sur la publication:	Annals of oncology, 24, 11, page (2761-2766), mdt275
Statut de publication:	Publié, 2013-11
Sujet CREF:	Hématologie
	Cancérologie
Mots-clés:	Breast cancer
	Her2
	Hera
	IHC intensity
	Trastuzumab
MeSH keywords:	Adult
	Antibodies, Monoclonal -- administration & dosage
	Antibodies, Monoclonal, Humanized -- administration & dosage
	Breast Neoplasms -- drug therapy -- epidemiology -- pathology
	Case-Control Studies
	Disease-Free Survival
	Female
	Humans
	In Situ Hybridization, Fluorescence
	Middle Aged
	Prognosis
	Receptor, ErbB-2 -- isolation & purification -- metabolism
	Treatment Outcome
Note générale:	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:0923-7534
	info:doi/10.1093/annonc/mdt275
	info:pii/mdt275
	info:scp/84887060197
	info:pmid/23894039